Antiretroviral therapy timing impacts latent tuberculosis infection reactivation in a Mycobacterium tuberculosis/SIV coinfection model.

MLA

Sharan, Riti, et al. “Antiretroviral Therapy Timing Impacts Latent Tuberculosis Infection Reactivation in a Mycobacterium Tuberculosis/SIV Coinfection Model.” The Journal of Clinical Investigation, vol. 132, no. 3, Feb. 2022. EBSCOhost, https://doi.org/10.1172/JCI153090.

APA

Sharan, R., Ganatra, S. R., Bucsan, A. N., Cole, J., Singh, D. K., Alvarez, X., Gough, M., Alvarez, C., Blakley, A., Ferdin, J., Thippeshappa, R., Singh, B., Escobedo, R., Shivanna, V., Dick, E. J., Jr, Hall-Ursone, S., Khader, S. A., Mehra, S., Rengarajan, J., & Kaushal, D. (2022). Antiretroviral therapy timing impacts latent tuberculosis infection reactivation in a Mycobacterium tuberculosis/SIV coinfection model. The Journal of Clinical Investigation, 132(3). https://doi.org/10.1172/JCI153090

Chicago

Sharan, Riti, Shashank R Ganatra, Allison N Bucsan, Journey Cole, Dhiraj K Singh, Xavier Alvarez, Maya Gough, et al. 2022. “Antiretroviral Therapy Timing Impacts Latent Tuberculosis Infection Reactivation in a Mycobacterium Tuberculosis/SIV Coinfection Model.” The Journal of Clinical Investigation 132 (3). doi:10.1172/JCI153090.